Professional Medical Writer Assistance in Oncology Clinical Trials

RAMEZ KOUZY,†a,b,† JOSEPH ABJAOUDE,†a,b TIMOTHY A. LIN,†c AUSTIN B. MILLER,†d AMIT JETHANANDANI,†
ANDRES F. ESPINOZA,b VIVEK VERMA,a CLIFTON D. FULLER,a BRUCE D. MINSKY,a CLAUS RÖDEL,f,g,h,i CULLEN M. TANIGUCHI,a,b,†
ETHAN B. LUDMIR,a,b
dThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA; bBaylor College of Medicine, Houston, Texas, USA; cThe Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; dThe University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA; eThe University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, USA; fUniversity of Frankfurt, Frankfurt, Germany; gGerman Cancer Research Center, Heidelberg, Germany; hGerman Cancer Consortium, Frankfurt, Germany; iFrankfurt Cancer Institute, Frankfurt, Germany
†Contributed equally as first authors
‡Contributed equally as senior authors
Disclosures of potential conflicts of interest may be found at the end of this article.

ABSTRACT

Background. The use of professional medical writers (PMWs) has been historically low, but contemporary data regarding PMW usage are scarce. In this study, we sought to quantify PMW use in oncologic phase III randomized controlled trials (RCTs).

Methods. We performed a database query through ClinicalTrials.gov to identify cancer-specific phase III RCTs; we then identified whether a PMW was involved in writing the associated trial manuscript reporting primary endpoint results.

Results. Two-hundred sixty trials of 600 (43.3%) used a PMW. Industry-funded trials used PMWs more often than nonindustry trials (54.9% vs. 3.0%, p < .001). Increased PMW usage was further noted among trials meeting their primary endpoint (53.4% vs. 32.9%, p < .001) and trials that led to subsequent Food and Drug Administration approval (63.1% vs. 36.3%, p < .001). By treatment interventions, PMW use was highest among systemic therapy trials (50.2%). Lastly, the use of PMWs increased significantly over time (odds ratio: 1.11/year, p = .001).

Conclusion. PMW use rates are high among industry-funded trials. We urge continued and increased transparency in reporting the funding and use of PMWs. The Oncologist 2020;25:e1812–e1815

INTRODUCTION

Academic publishing remains the cornerstone of cancer research and scientific communication of clinical trials. Over the years, there has been increasing interest in the use of professional medical writers (PMWs) to help investigators improve quality of writing and/or reduce the time to publication [1]. Use rates of such PMW services have historically been low, but contemporary data regarding PMW usage remain scarce [2]. With an increasing role of industry sponsorship in cancer clinical trials [3], we sought to characterize the rate of PMW use among reports of phase III cancer clinical trial results, focusing on factors associated with PMW usage.

METHODS

Study Design and Data Collection

We performed a database query through the ClinicalTrials.gov registry to search for oncologic phase III randomized controlled trials (RCTs) conducted between 2003 and 2018. This search yielded a total of 1,239 trials, of which we selected trials that were cancer-specific, multiarm, interventional, randomized, phase III studies with published primary endpoint results (Fig. 1) [4]. Trial factors were extracted from ClinicalTrials.gov, the protocol, and/or the manuscript. For all 600 included trials, we searched the associated manuscripts, including the methodology and the acknowledgments sections, for disclosures regarding use of professional assistance in writing the manuscript.

Pearson’s Chi-squared tests were used to assess the association between individual trial factors and the use of PMWs. Those variables with Pearson’s Chi-squared p < .05 on univariate analysis were subsequently included in multivariable binary logistic regression modeling, which was used to identify those variables independently associated with PMW use. Statistical significance was set a priori at α = .05. All analyses were performed using IBM SPSS version 26 (IBM, Armonk, NY) [5].

Correspondence: Cullen M. Taniguchi, M.D., Ph.D., The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1050, Houston, Texas 77030, USA. Telephone: 713-792-5863; e-mail: ctaniguchi@mdanderson.org; or Ethan B. Ludmir, M.D., The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1422, Houston, Texas 77030, USA. Telephone: 713-745-5269; e-mail: ebludmir@mdanderson.org; or Ethan B. Ludmir, M.D., The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1050, Houston, Texas 77030, USA. Telephone: 713-792-5863; e-mail: ebludmir@mdanderson.org. Received May 7, 2020; accepted for publication August 14, 2020; published Online First on September 17, 2020. http://dx.doi.org/10.1634/theoncologist.2020-0406

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The Oncologist 2020;25:e1812–e1815 www.TheOncologist.com © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
In total, 600 trials met the inclusion criteria (Fig. 1), of which 260 (43.3%) used a PMW. Table 1 highlights trial factors associated with PMW use. Industry-funded trials used PMWs more often than nonindustry trials (54.9% vs. 3.0%, \(p < .001\)). Notably, financial support to PMWs was nearly exclusively provided by biopharmaceutical industry sponsors (247/260, 95.0%). On the other hand, cooperative group sponsorship was associated with lower PMW use (6.4% vs. 60.3%, \(p < .001\)). When analyzing intervention modality, trials of systemic therapy had higher PMW usage compared with trials of radiation therapy, surgery, or supportive care (50.2% vs. 6.7% vs. 0.0% vs. 22.3%, respectively, \(p < .001\)). Furthermore, trials with a first author affiliated with an institution from a non-English-speaking country relied more on PMW use when compared with trials with English-speaking country first authors (58.8% vs. 34.3%, respectively, \(p < .001\)). Increased PMW usage was also identified among trials that successfully met their primary endpoint (53.4% vs. 32.9%, \(p < .001\)). Lastly, the use of PMWs increased significantly over time (odds ratio [OR]: 1.11/year, \(p = .001\)). On multivariable binary logistic regression, Food and Drug Administration approval, trial disease site, and first author’s institutional affiliation by nationality were not independently associated with PMW use. On the other hand, industry funding (OR: 13.8, \(p = .001\)), cooperative group sponsorship (OR: 0.1, \(p < .001\)), and intervention modality (\(p = .01\)) were all independently associated with the use of PMWs.

**DISCUSSION**

The use of PMW assistance in communicating clinical trial results has been historically low, with scant information on PMW use in oncology trials. Such information remains imperative for full and transparent scientific communication, particularly given the increasing attention to the role of conflicts of interest in clinical oncology.

The observed rate of PMW usage among phase III oncology trials (43.3%) is strikingly higher than prior data from a 2006 report, in which writing assistance was noted in only 6% of publications. In addition, we show that PMW usage among industry-sponsored trials was markedly higher than the previous rate reported among industry-sponsored studies (54.9% vs. 10%) [2]. These comparator data from 2006 examined articles published in top journals from various disciplines in medicine [2], whereas our study examined cancer-specific phase III trials irrespective of publication journal. It is possible that the higher PMW rates noted here are due to increased rates of writing assistance disclosure since 2006, as advocated for by professional writing societies. Yet, it is noteworthy that disclosure is still not universally mandated, and our findings may still underestimate the true extent of PMW usage [6]. Alternatively, higher use of PMWs in the present study may reflect a greater proportion of industry-sponsored oncology trials in general [7]. PMWs may also be increasingly used in order to expedite data reporting and publication; the observation of increased PMW usage among positive trials and trials that led to subsequent regulatory approval may support this hypothesis.

Prior data have demonstrated that PMW usage is associated with a higher rate of adherence to the Consolidated Standards of Reporting Trials criteria for reporting [2]. Although manuscript quality and readability might therefore be enhanced because of PMWs, the issue of potential conflicts of interest, while understudied, remains of potential concern [8].

Our study has several limitations. First, our search was limited to manuscript-reported disclosures of PMW support in manuscript drafting, potentially underestimating the true rate of PMW use. Ghostwriting of manuscripts would not be captured with our methodology [9]. Second, the differential roles of PMWs across manuscripts was not assessed; PMWs may provide proofreading and editorial assistance. Because those roles were excluded from our study (highlighted in Fig. 1), the true rate of PMW assistance might be higher. Although these levels of PMW involvement are not typically disclosed, it is conceivable that the extent of PMW input may differ based on factors such as industry sponsorship, trial success, and subsequent request for regulatory approval.
CONCLUSION

This study represents the first large-scale modern analysis of PMW use and funding among cancer clinical trials, particularly relevant with the growing role of industry sponsorship among clinical oncology studies. Although prior data suggest that the use of PMWs may improve quality [1], others have raised concerns that PMWs may have a disproportionate effect in shaping the conclusions of industry-sponsored trials [8], and therefore sway acceptance of data. We demonstrate high rates of PMW use among industry-sponsored trials; this highlights the need for continued and increased transparency in reporting the funding, use, and role of professional writing assistance [2, 6].

ACKNOWLEDGMENTS

Clifton D. Fuller received funding and salary support unrelated to this project from the National Institutes of Health (NIH), including a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787-01), the National Institute for Dental and Craniofacial Research Establishing Outcome Measures Award (1R01DE025248/R56DE025248) and an Academic Industrial Partnership Grant (R01DE028290); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer.

Table 1. Trial factors associated with the use of professional medical writers

| Trial factors                        | Medical writer use n (%) | Chi-square p value | Multivariate binary logistic regression Odds ratio p value |
|--------------------------------------|--------------------------|--------------------|----------------------------------------------------------|
| Industry funding of triala           |                          |                    |                                                          |
| Yes                                  | 256/466 (54.9)           | <.001              | 13.8 (3.1–61.2) .001                                       |
| No                                   | 4/134 (3.0)              |                    |                                                          |
| Cooperative group triala             |                          | <.001              |                                                          |
| Yes                                  | 12/189 (6.3)             |                    | 0.1 (0.03–0.14) .001                                       |
| No                                   | 248/411 (60.3)           |                    |                                                          |
| Disease siteb                        |                          | .01                | .43                                                       |
| Breast                               | 40/105 (38.1)            |                    |                                                          |
| Gastrointestinal                     | 46/76 (60.5)             |                    |                                                          |
| Genitourinary                        | 32/70 (45.7)             |                    |                                                          |
| Head and neck                        | 11/23 (47.8)             |                    |                                                          |
| Hematologic                          | 46/118 (39.0)            |                    |                                                          |
| Lungs                                | 51/88 (58.0)             |                    |                                                          |
| Modalityc                            |                          | <.001              | .01                                                       |
| Systemic therapyd                    | 234/466 (50.2)           |                    |                                                          |
| Radiotherapy                         | 1/15 (6.7)               |                    |                                                          |
| Surgery                              | 0/7 (0.0)                |                    |                                                          |
| Supportive caree                     | 25/112 (22.3)            |                    |                                                          |
| Trial success (PEP met)              |                          | <.001              | .09                                                       |
| Yes                                  | 163/305 (53.4)           |                    | 1.6 (0.9–2.7) .09                                         |
| No                                   | 97/295 (32.9)            |                    |                                                          |
| Subsequent FDA approvalf             |                          | <.001              | .71                                                       |
| Yes                                  | 99/157 (63.1)            |                    | 1.1 (0.6–2.0) .71                                         |
| No                                   | 161/443 (36.3)           |                    |                                                          |
| First author from English-speaking countryg |              | <.001              |                                                          |
| Yes                                  | 130/379 (34.3)           |                    | 0.7 (0.5–1.1) .13                                         |
| No                                   | 130/221 (58.8)           |                    |                                                          |

*aIndustry funding and cooperative group sponsorship were considered independent variables because some trials were both industry funded and performed through a cooperative group.

bAnalysis by disease site was limited to those studies with a defined single disease site.

cModality addressed the primary intervention as part of the randomization.

dSystemic therapy trials, including chemotherapy, targeted systemic agents, immunotherapy, and others, accounted for most trials by modality; they used systemic therapies to improve disease-related outcomes (e.g., overall survival, disease-free survival).

eSupportive care trials were those where the intervention aimed to reduce disease- or treatment-related toxic effects as the primary endpoint.

fThe trial led to subsequent FDA approval of the drug being tested.

gBased on affiliation with an institution located in English-speaking countries: U.S., U.K., Canada, and Australia.

Abbreviations: —, no data; FDA, Food and Drug Administration; PEP, primary endpoint.

© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Imaging Program (P30CA016672) and an NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50 CA097007); NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825) National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679); and an NSF Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) standard grant (NSF 1933369); the Stiefel Oropharyngeal Research Fund of the University of Texas MD Anderson Cancer, and the MD Anderson Program in Image-guided Cancer Therapy.

DISCLOSURES
Clifton D. Fuller: Elekta AB (RF, H, Other: travel funding). The other authors indicated no financial relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patient holder; (SAB) Scientific advisory board

REFERENCES
1. Gattrell WT, Hopewell S, Young K et al. Professional medical writing support and the quality of randomised controlled trial reporting: A cross-sectional study. BMJ Open 2016;6:e010329.
2. Woolley KL, Ely JA, Woolley MJ et al. Declaration of medical writing assistance in international peer-reviewed publications. JAMA 2006;296:929–934.
3. Neel DV, Shulman DS, Ma C et al. Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Med 2020;9:4495–4500.
4. Ludmir EB, Mainwaring W, Lin TA et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol 2019;5.
5. IBM Corp. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp. 2019.
6. DeTora LM, Carey MA, Toroser D et al. Ghostwriting in biomedicine: A review of the published literature. Curr Med Res Opin 2019;35:1643–1651.
7. Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health funding for clinical trials registered in clinicaltrials.gov. JAMA 2015;314:2566–2567.
8. Prasad V, Rajkumar SV. Conflict of interest in academic oncology: Moving beyond the blame game and forging a path forward. Blood Cancer J 2016;6:e489.
9. Woolley KL. Goodbye ghostwriters: How to work ethically and efficiently with professional medical writers. Chest 2006;130:921–923.